Miranda E Orr, Eithan Kotkowski, Paulino Ramirez, Darcy Bair-Kelps, Qianqian Liu, Charles Brenner, Mark S Schmidt, Peter T Fox, Anis Larbi, Crystal Tan, Glenn Wong, Jonathan Gelfond, Bess Frost, Sara Espinoza, Nicolas Musi, Becky Powers
Nicotinamide riboside (NR) increases blood levels of NAD+, a cofactor central to energy metabolism, and improves brain function in some rodent models of neurodegeneration. We conducted a placebo-controlled randomized pilot study with the primary objective of determining safety of NR in older adults with mild cognitive impairment (MCI). Twenty subjects with MCI were randomized to receive placebo or NR using dose escalation to achieve, and maintain, a final dose of 1 g/day over a 10-week study duration. The primary outcome was post-treatment change from baseline measures of cognition (Montreal Cognitive Assessment, MoCA)...
November 23, 2023: GeroScience